Peter Klivenyi, MD PhD - Publications

Affiliations: 
Neurology University of Pécs, Hungary, Pécs, Hungary 

78 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2020 Zádori D, Szalárdy L, Reisz Z, Kovacs GG, Maszlag-Török R, Ajeawung NF, Vécsei L, Campeau PM, Klivényi P. Clinicopathological Relationships in an Aged Case of DOORS Syndrome With a p.Arg506X Mutation in the Gene. Frontiers in Neurology. 11: 767. PMID 32849222 DOI: 10.3389/Fneur.2020.00767  0.304
2020 Salamon A, Zádori D, Szpisjak L, Klivényi P, Vécsei L. Fixed-dose combination therapy for Parkinson's disease with a spotlight on entacapone in the past 20 years: a reduced pill burden and a simplified dosing regime. Expert Opinion On Pharmacotherapy. 1-14. PMID 32808807 DOI: 10.1080/14656566.2020.1806237  0.422
2020 Takáts A, Aschermann Z, Vécsei L, Klivényi P, Dézsi L, Zádori D, Valikovics A, Varannai L, Onuk K, Kinczel B, Kovács N. [Advanced Parkinson's disease characteristics in clinical practice: Results from the OBSERVE-PD study and sub-analysis of the Hungarian data]. Ideggyogyaszati Szemle. 73: 261-268. PMID 32750243 DOI: 10.18071/Isz.73.0261  0.374
2020 Nánási N, Veres G, Cseh EK, Martos D, Hadady L, Klivényi P, Vécsei L, Zádori D. The assessment of possible gender-related effect of endogenous striatal alpha-tocopherol level on MPTP neurotoxicity in mice. Heliyon. 6: e04425. PMID 32685739 DOI: 10.1016/J.Heliyon.2020.E04425  0.414
2020 Salamon A, Maszlag-Török R, Veres G, Boros FA, Vágvölgyi-Sümegi E, Somogyi A, Vécsei L, Klivényi P, Zádori D. Cerebellar Predominant Increase in mRNA Expression Levels of Sirt1 and Sirt3 Isoforms in a Transgenic Mouse Model of Huntington's Disease. Neurochemical Research. PMID 32524313 DOI: 10.1007/S11064-020-03069-0  0.388
2020 Boros FA, Maszlag-Török R, Vécsei L, Klivényi P. Increased level of NEAT1 long non-coding RNA is detectable in peripheral blood cells of patients with Parkinson's disease. Brain Research. 1730: 146672. PMID 31953211 DOI: 10.1016/J.Brainres.2020.146672  0.346
2019 Salamon A, Zádori D, Szpisjak L, Klivényi P, Vécsei L. Neuroprotection in Parkinson's disease: facts and hopes. Journal of Neural Transmission (Vienna, Austria : 1996). PMID 31828513 DOI: 10.1007/S00702-019-02115-8  0.393
2019 Illés A, Csabán D, Grosz Z, Balicza P, Gézsi A, Molnár V, Bencsik R, Gál A, Klivényi P, Molnar MJ. The Role of Genetic Testing in the Clinical Practice and Research of Early-Onset Parkinsonian Disorders in a Hungarian Cohort: Increasing Challenge in Genetic Counselling, Improving Chances in Stratification for Clinical Trials. Frontiers in Genetics. 10: 1061. PMID 31737044 DOI: 10.3389/Fgene.2019.01061  0.32
2019 Salamon A, Zádori D, Szpisjak L, Klivényi P, Vécsei L. Opicapone for the treatment of Parkinson's disease: an update. Expert Opinion On Pharmacotherapy. 1-7. PMID 31670988 DOI: 10.1080/14656566.2019.1681971  0.338
2019 Boros FA, Török R, Vágvölgyi-Sümegi E, Pesei ZG, Klivényi P, Vécsei L. Assessment of risk factor variants of LRRK2, MAPT, SNCA and TCEANC2 genes in Hungarian sporadic Parkinson's disease patients. Neuroscience Letters. 706: 140-145. PMID 31085292 DOI: 10.1016/J.Neulet.2019.05.014  0.366
2019 Szpisjak L, Zadori D, Klivenyi P, Vecsei L. Clinical characteristics and possible drug targets in autosomal dominant spinocerebellar ataxias. Cns & Neurological Disorders Drug Targets. PMID 30864514 DOI: 10.2174/1871527318666190311155846  0.312
2019 Salamon A, Torok R, Sumegi E, Boros F, Pesei ZG, Fort Molnar M, Veres G, Zadori D, Vecsei L, Klivenyi P. The effect of physical stimuli on the expression level of key elements in mitochondrial biogenesis. Neuroscience Letters. 698: 13-18. PMID 30611892 DOI: 10.1016/J.Neulet.2019.01.003  0.317
2018 Klivényi P, Vécsei L. [The treatment of advanced Parkinson's disease]. Ideggyogyaszati Szemle. 71: 377-383. PMID 30604936 DOI: 10.18071/Isz.71.0377  0.322
2018 Boros FA, Klivényi P, Toldi J, Vécsei L. Indoleamine 2,3-dioxygenase as a novel therapeutic target for Huntington's disease. Expert Opinion On Therapeutic Targets. 1-13. PMID 30449219 DOI: 10.1080/14728222.2019.1549231  0.351
2018 Szalardy L, Molnar MF, Zadori D, Cseh EK, Veres G, Kovacs GG, Vecsei L, Klivenyi P. Non-motor Behavioral Alterations of PGC-1α-Deficient Mice - A Peculiar Phenotype With Slight Male Preponderance and No Apparent Progression. Frontiers in Behavioral Neuroscience. 12: 180. PMID 30210314 DOI: 10.3389/Fnbeh.2018.00180  0.316
2018 Zádori D, Veres G, Szalárdy L, Klivényi P, Vécsei L. Alzheimer's Disease: Recent Concepts on the Relation of Mitochondrial Disturbances, Excitotoxicity, Neuroinflammation, and Kynurenines. Journal of Alzheimer's Disease : Jad. 62: 523-547. PMID 29480191 DOI: 10.3233/Jad-170929  0.345
2017 Tripolszki K, Török D, Goudenège D, Farkas K, Sulák A, Török N, Engelhardt JI, Klivényi P, Procaccio V, Nagy N, Széll M. High-throughput sequencing revealed a novel SETX mutation in a Hungarian patient with amyotrophic lateral sclerosis. Brain and Behavior. 7: e00669. PMID 28413711 DOI: 10.1002/Brb3.669  0.312
2017 Juhász A, Aschermann Z, Ács P, Janszky J, Kovács M, Makkos A, Harmat M, Tényi D, Karádi K, Komoly S, Takáts A, Tóth A, Nagy H, Klivényi P, Dibó G, et al. Levodopa/carbidopa intestinal gel can improve both motor and non-motor experiences of daily living in Parkinson's disease: An open-label study. Parkinsonism & Related Disorders. PMID 28185758 DOI: 10.1016/J.Parkreldis.2017.02.001  0.353
2017 Torok R, Salamon A, Sumegi E, Zadori D, Veres G, Molnar MF, Vecsei L, Klivenyi P. Effect of MPTP on mRNA expression of PGC-1α in mouse brain. Brain Research. PMID 28161458 DOI: 10.1016/J.Brainres.2017.01.032  0.306
2016 Aschermann Z, Dibó G, Klivényi P, Kovács N, Kovács T, Takáts A, Tamás G, Varannai L. [Recommendation for treatment options in advanced Parkinson's disease]. Ideggyogyaszati Szemle. 69: 367-372. PMID 29733553 DOI: 10.18071/Isz.69.0367  0.337
2016 Molnár MF, Török R, Szalárdy L, Sümegi E, Vécsei L, Klivényi P. High-dose 1,25-dihydroxyvitamin D supplementation elongates the lifespan of Huntington's disease transgenic mice. Acta Neurobiologiae Experimentalis. 76: 176-81. PMID 27685770 DOI: 10.21307/Ane-2017-017  0.371
2016 Tamás G, Kelemen A, Radics P, Valálik I, Heldman D, Klivényi P, Vécsei L, Hidasi E, Halász L, Kis D, Barsi P, Golopencza P, Erőss L. Effect of subthalamic stimulation on distal and proximal upper limb movements in Parkinson's disease. Brain Research. PMID 27543337 DOI: 10.1016/J.Brainres.2016.08.019  0.311
2016 Ács P, Molnár MJ, Klivényi P, Kálmán B. [GENETICALLY DETERMINED DISEASES ASSOCIATED WITH PATHOLOGICAL BRAIN IRON ACCUMULATION AND NEURODEGENERATION]. IdeggyóGyáSzati Szemle. 69: 157-66. PMID 27468605 DOI: 10.18071/Isz.69.0157  0.305
2016 Szalardy L, Molnar M, Torok R, Zadori D, Kovacs GG, Vecsei L, Klivenyi P. Lack of age-related clinical progression in PGC-1α-deficient mice - implications for mitochondrial encephalopathies. Behavioural Brain Research. PMID 27424777 DOI: 10.1016/J.Bbr.2016.07.021  0.402
2016 Szalardy L, Molnar M, Torok R, Zadori D, Vecsei L, Klivenyi P, Liberski P, Kovacs GG. Histopathological comparison of Kearns-Sayre syndrome and PGC-1α-deficient mice suggests a novel concept for vacuole formation in mitochondrial encephalopathy. Folia Neuropathologica / Association of Polish Neuropathologists and Medical Research Centre, Polish Academy of Sciences. 54: 9-22. PMID 27179217 DOI: 10.5114/Fn.2016.58911  0.355
2016 Zádori D, Veres G, Szalárdy L, Klivényi P, Fülöp F, Toldi J, Vécsei L. Inhibitors of the kynurenine pathway as neurotherapeutics: a patent review (2012-2015). Expert Opinion On Therapeutic Patents. PMID 27172114 DOI: 10.1080/13543776.2016.1189531  0.305
2015 Török R, Zádori D, Török N, Csility É, Vécsei L, Klivényi P. An assessment of the frequency of mutations in the GBA and VPS35 genes in Hungarian patients with sporadic Parkinson's disease. Neuroscience Letters. PMID 26547032 DOI: 10.1016/J.Neulet.2015.11.001  0.304
2015 Szalárdy L, Zádori D, Klivényi P, Toldi J, Vécsei L. Electron Transport Disturbances and Neurodegeneration: From Albert Szent-Györgyi's Concept (Szeged) till Novel Approaches to Boost Mitochondrial Bioenergetics. Oxidative Medicine and Cellular Longevity. 2015: 498401. PMID 26301042 DOI: 10.1155/2015/498401  0.396
2015 Török N, Török R, Szolnoki Z, Somogyvári F, Klivényi P, Vécsei L. The Genetic Link between Parkinson's Disease and the Kynurenine Pathway Is Still Missing. Parkinson's Disease. 2015: 474135. PMID 25785227 DOI: 10.1155/2015/474135  0.34
2015 Veres G, Molnár M, Zádori D, Szentirmai M, Szalárdy L, Török R, Fazekas E, Ilisz I, Vécsei L, Klivényi P. Central nervous system-specific alterations in the tryptophan metabolism in the 3-nitropropionic acid model of Huntington's disease. Pharmacology, Biochemistry, and Behavior. 132: 115-124. PMID 25773340 DOI: 10.1016/J.Pbb.2015.03.002  0.412
2015 Török R, Kónya JA, Zádori D, Veres G, Szalárdy L, Vécsei L, Klivényi P. mRNA expression levels of PGC-1α in a transgenic and a toxin model of Huntington's disease. Cellular and Molecular Neurobiology. 35: 293-301. PMID 25319408 DOI: 10.1007/S10571-014-0124-Z  0.322
2014 Zádori D, Veres G, Szalárdy L, Klivényi P, Toldi J, Vécsei L. Glutamatergic dysfunctioning in Alzheimer's disease and related therapeutic targets. Journal of Alzheimer's Disease : Jad. 42: S177-87. PMID 24670398 DOI: 10.3233/Jad-132621  0.321
2013 Török R, Török N, Szalardy L, Plangar I, Szolnoki Z, Somogyvari F, Vecsei L, Klivenyi P. Association of vitamin D receptor gene polymorphisms and Parkinson's disease in Hungarians. Neuroscience Letters. 551: 70-4. PMID 23880018 DOI: 10.1016/J.Neulet.2013.07.014  0.304
2013 Szalardy L, Zadori D, Plangar I, Vecsei L, Weydt P, Ludolph AC, Klivenyi P, Kovacs GG. Neuropathology of partial PGC-1α deficiency recapitulates features of mitochondrial encephalopathies but not of neurodegenerative diseases. Neuro-Degenerative Diseases. 12: 177-88. PMID 23406886 DOI: 10.1159/000346267  0.396
2013 Molnar M, Szalardy L, Zadori D, Vecsei L, Klivenyi P. Revisiting the observation of anxiety-like behavior and assessing phenotypic progression in PGC-1α-deficient mice Journal of the Neurological Sciences. 333: e727. DOI: 10.1016/J.Jns.2013.07.2508  0.318
2012 Szalardy L, Zadori D, Toldi J, Fulop F, Klivenyi P, Vecsei L. Manipulating kynurenic acid levels in the brain - on the edge between neuroprotection and cognitive dysfunction. Current Topics in Medicinal Chemistry. 12: 1797-806. PMID 23030614 DOI: 10.2174/156802612803989264  0.308
2012 Nemeth D, Dye CD, Sefcsik T, Janacsek K, Turi Z, Londe Z, Klivenyi P, Kincses ZT, Szabó N, Vecsei L, Ullman MT. Language deficits in pre-symptomatic Huntington's disease: evidence from Hungarian. Brain and Language. 121: 248-53. PMID 22538085 DOI: 10.1016/J.Bandl.2012.04.001  0.315
2012 Szalardy L, Klivenyi P, Zadori D, Fulop F, Toldi J, Vecsei L. Mitochondrial disturbances, tryptophan metabolites and neurodegeneration: medicinal chemistry aspects. Current Medicinal Chemistry. 19: 1899-920. PMID 22429096 DOI: 10.2174/092986712800167365  0.372
2011 Klivenyi P, Vecsei L. Pharmacological models of Parkinson's disease in rodents. Methods in Molecular Biology (Clifton, N.J.). 793: 211-27. PMID 21913103 DOI: 10.1007/978-1-61779-328-8_14  0.41
2010 Spitzer P, Klafki HW, Blennow K, Buée L, Esselmann H, Herruka SK, Jimenez C, Klivenyi P, Lewczuk P, Maler JM, Markus K, Meyer HE, Morris C, Müller T, Otto M, et al. cNEUPRO: Novel Biomarkers for Neurodegenerative Diseases. International Journal of Alzheimer's Disease. 2010. PMID 20886057 DOI: 10.4061/2010/548145  0.307
2010 Vamos E, Voros K, Vecsei L, Klivenyi P. Neuroprotective effects of L-carnitine in a transgenic animal model of Huntington's disease. Biomedicine & Pharmacotherapy = Biomã©Decine & Pharmacothã©Rapie. 64: 282-6. PMID 19932584 DOI: 10.1016/J.Biopha.2009.06.020  0.412
2010 Klivenyi P, Vecsei L. Novel therapeutic strategies in Parkinson's disease. European Journal of Clinical Pharmacology. 66: 119-25. PMID 19834698 DOI: 10.1007/S00228-009-0742-4  0.362
2009 Vamos E, Voros K, Zadori D, Vecsei L, Klivenyi P. Neuroprotective effects of probenecid in a transgenic animal model of Huntington's disease. Journal of Neural Transmission (Vienna, Austria : 1996). 116: 1079-86. PMID 19551467 DOI: 10.1007/S00702-009-0253-6  0.453
2009 Vamos E, Csati A, Vecsei L, Klivenyi P. Effects of valproate on the dopaminergic system in mice. Neurological Research. 31: 217-9. PMID 18768113 DOI: 10.1179/174313208X346099  0.402
2007 Hartai Z, Klivenyi P, Janaky T, Penke B, Dux L, Vecsei L. Peripheral kynurenine metabolism in focal dystonia. Medicinal Chemistry (ShäRiqah (United Arab Emirates)). 3: 285-8. PMID 17504201 DOI: 10.2174/157340607780620707  0.336
2007 Vamos E, Csati A, Klivenyi P, Vecsei L. 1.319 Effects of valproate on dopaminergic system in mice Parkinsonism & Related Disorders. 13. DOI: 10.1016/S1353-8020(08)70554-6  0.411
2006 Klivenyi P, Bende Z, Hartai Z, Penke Z, Nemeth H, Toldi J, Vecsei L. Behaviour changes in a transgenic model of Huntington's disease. Behavioural Brain Research. 169: 137-41. PMID 16443291 DOI: 10.1016/J.Bbr.2006.01.003  0.424
2006 Klivenyi P, Siwek D, Gardian G, Yang L, Starkov A, Cleren C, Ferrante RJ, Kowall NW, Abeliovich A, Beal MF. Mice lacking alpha-synuclein are resistant to mitochondrial toxins. Neurobiology of Disease. 21: 541-8. PMID 16298531 DOI: 10.1016/J.Nbd.2005.08.018  0.788
2005 Klivenyi P, Kekesi KA, Hartai Z, Juhasz G, Vecsei L. Effects of mitochondrial toxins on the brain amino acid concentrations. Neurochemical Research. 30: 1421-7. PMID 16341939 DOI: 10.1007/S11064-005-8512-X  0.368
2005 Hartai Z, Klivenyi P, Janaky T, Penke B, Dux L, Vecsei L. Kynurenine metabolism in plasma and in red blood cells in Parkinson's disease. Journal of the Neurological Sciences. 239: 31-5. PMID 16099471 DOI: 10.1016/J.Jns.2005.07.006  0.339
2005 Hartai Z, Klivenyi P, Janaky T, Penke B, Dux L, Vecsei L. Kynurenine metabolism in multiple sclerosis. Acta Neurologica Scandinavica. 112: 93-6. PMID 16008534 DOI: 10.1111/J.1600-0404.2005.00442.X  0.305
2005 Gardian G, Browne SE, Choi DK, Klivenyi P, Gregorio J, Kubilus JK, Ryu H, Langley B, Ratan RR, Ferrante RJ, Beal MF. Neuroprotective effects of phenylbutyrate in the N171-82Q transgenic mouse model of Huntington's disease. The Journal of Biological Chemistry. 280: 556-63. PMID 15494404 DOI: 10.1074/Jbc.M410210200  0.793
2004 Klivenyi P, Gardian G, Calingasan NY, Yang L, von Borstel R, Saydoff J, Browne SE, Beal MF. Neuroprotective effects of oral administration of triacetyluridine against MPTP neurotoxicity. Neuromolecular Medicine. 6: 87-92. PMID 15970626 DOI: 10.1385/Nmm:6:2-3:087  0.796
2004 Gardian G, Yang L, Cleren C, Calingasan NY, Klivenyi P, Beal MF. Neuroprotective effects of phenylbutyrate against MPTP neurotoxicity. Neuromolecular Medicine. 5: 235-41. PMID 15626823 DOI: 10.1385/Nmm:5:3:235  0.799
2004 Klivenyi P, Calingasan NY, Starkov A, Stavrovskaya IG, Kristal BS, Yang L, Wieringa B, Beal MF. Neuroprotective mechanisms of creatine occur in the absence of mitochondrial creatine kinase. Neurobiology of Disease. 15: 610-7. PMID 15056469 DOI: 10.1016/J.Nbd.2003.12.014  0.732
2004 Klivenyi P, Starkov AA, Calingasan NY, Gardian G, Browne SE, Yang L, Bubber P, Gibson GE, Patel MS, Beal MF. Mice deficient in dihydrolipoamide dehydrogenase show increased vulnerability to MPTP, malonate and 3-nitropropionic acid neurotoxicity. Journal of Neurochemistry. 88: 1352-60. PMID 15009635 DOI: 10.1046/J.1471-4159.2003.02263.X  0.804
2004 Klivenyi P, Kiaei M, Gardian G, Calingasan NY, Beal MF. Additive neuroprotective effects of creatine and cyclooxygenase 2 inhibitors in a transgenic mouse model of amyotrophic lateral sclerosis. Journal of Neurochemistry. 88: 576-82. PMID 14720207 DOI: 10.1046/J.1471-4159.2003.02160.X  0.79
2003 Klivenyi P, Gardian G, Calingasan NY, Yang L, Beal MF. Additive neuroprotective effects of creatine and a cyclooxygenase 2 inhibitor against dopamine depletion in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of Parkinson's disease. Journal of Molecular Neuroscience : Mn. 21: 191-8. PMID 14645986 DOI: 10.1385/Jmn:21:3:191  0.798
2003 Barberi T, Klivenyi P, Calingasan NY, Lee H, Kawamata H, Loonam K, Perrier AL, Bruses J, Rubio ME, Topf N, Tabar V, Harrison NL, Beal MF, Moore MA, Studer L. Neural subtype specification of fertilization and nuclear transfer embryonic stem cells and application in parkinsonian mice. Nature Biotechnology. 21: 1200-7. PMID 14502203 DOI: 10.1038/Nbt870  0.512
2003 Klivenyi P, Ferrante RJ, Gardian G, Browne S, Chabrier PE, Beal MF. Increased survival and neuroprotective effects of BN82451 in a transgenic mouse model of Huntington's disease. Journal of Neurochemistry. 86: 267-72. PMID 12807446 DOI: 10.1046/J.1471-4159.2003.T01-1-01868.X  0.8
2003 Klivenyi P, Ferrante RJ, Gardian G, Browne S, Chabrier PE, Beal MF. Erratum: Increased survival and neuroprotective effects of BN82451 in a transgenic mouse model of Huntington's disease (Journal of Neurochemistry (2003) 86 (267-272)) Journal of Neurochemistry. 87. DOI: 10.1046/J.1471-4159.2003.01868.X  0.79
2001 Andreassen OA, Ferrante RJ, Klivenyi P, Klein AM, Dedeoglu A, Albers DS, Kowall NW, Beal MF. Transgenic ALS mice show increased vulnerability to the mitochondrial toxins MPTP and 3-nitropropionic acid. Experimental Neurology. 168: 356-63. PMID 11259123 DOI: 10.1006/Exnr.2001.7627  0.659
2001 Klivenyi P, Karg E, Rozsa C, Horvath R, Komoly S, Nemeth I, Turi S, Vecsei L. alpha-Tocopherol/lipid ratio in blood is decreased in patients with Leber's hereditary optic neuropathy and asymptomatic carriers of the 11778 mtDNA mutation. Journal of Neurology, Neurosurgery, and Psychiatry. 70: 359-62. PMID 11181859 DOI: 10.1136/Jnnp.70.3.359  0.317
2001 Andreassen OA, Ferrante RJ, Dedeoglu A, Albers DW, Klivenyi P, Carlson EJ, Epstein CJ, Beal MF. Mice with a partial deficiency of manganese superoxide dismutase show increased vulnerability to the mitochondrial toxins malonate, 3-nitropropionic acid, and MPTP. Experimental Neurology. 167: 189-95. PMID 11161607 DOI: 10.1006/Exnr.2000.7525  0.674
2000 Andreassen OA, Dedeoglu A, Klivenyi P, Beal MF, Bush AI. N-acetyl-L-cysteine improves survival and preserves motor performance in an animal model of familial amyotrophic lateral sclerosis. Neuroreport. 11: 2491-3. PMID 10943709 DOI: 10.1097/00001756-200008030-00029  0.621
2000 Andreassen OA, Ferrante RJ, Hughes DB, Klivenyi P, Dedeoglu A, Ona VO, Friedlander RM, Beal MF. Malonate and 3-nitropropionic acid neurotoxicity are reduced in transgenic mice expressing a caspase-1 dominant-negative mutant. Journal of Neurochemistry. 75: 847-52. PMID 10899963 DOI: 10.1046/J.1471-4159.2000.0750847.X  0.633
2000 Klivenyi P, Andreassen OA, Ferrante RJ, Lancelot E, Reif D, Beal MF. Inhibition of neuronal nitric oxide synthase protects against MPTP toxicity. Neuroreport. 11: 1265-8. PMID 10817604 DOI: 10.1097/00001756-200004270-00024  0.767
2000 Jenkins BG, Klivenyi P, Kustermann E, Andreassen OA, Ferrante RJ, Rosen BR, Beal MF. Nonlinear decrease over time in N-acetyl aspartate levels in the absence of neuronal loss and increases in glutamine and glucose in transgenic Huntington's disease mice. Journal of Neurochemistry. 74: 2108-19. PMID 10800956 DOI: 10.1046/J.1471-4159.2000.0742108.X  0.628
2000 Andreassen OA, Ferrante RJ, Klivenyi P, Klein AM, Shinobu LA, Epstein CJ, Beal MF. Partial deficiency of manganese superoxide dismutase exacerbates a transgenic mouse model of amyotrophic lateral sclerosis. Annals of Neurology. 47: 447-55. PMID 10762155 DOI: 10.1002/1531-8249(200004)47:4<447::Aid-Ana7>3.0.Co;2-R  0.783
2000 Klivenyi P, Andreassen OA, Ferrante RJ, Dedeoglu A, Mueller G, Lancelot E, Bogdanov M, Andersen JK, Jiang D, Beal MF. Mice deficient in cellular glutathione peroxidase show increased vulnerability to malonate, 3-nitropropionic acid, and 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 20: 1-7. PMID 10627575 DOI: 10.1523/Jneurosci.20-01-00001.2000  0.785
1999 Matthews RT, Ferrante RJ, Klivenyi P, Yang L, Klein AM, Mueller G, Kaddurah-Daouk R, Beal MF. Creatine and cyclocreatine attenuate MPTP neurotoxicity. Experimental Neurology. 157: 142-9. PMID 10222117 DOI: 10.1006/Exnr.1999.7049  0.776
1999 Matthews RT, Klivenyi P, Mueller G, Yang L, Wermer M, Thomas CE, Beal MF. Novel free radical spin traps protect against malonate and MPTP neurotoxicity. Experimental Neurology. 157: 120-6. PMID 10222114 DOI: 10.1006/Exnr.1999.7045  0.738
1999 Klivenyi P, Ferrante RJ, Matthews RT, Bogdanov MB, Klein AM, Andreassen OA, Mueller G, Wermer M, Kaddurah-Daouk R, Beal MF. Neuroprotective effects of creatine in a transgenic animal model of amyotrophic lateral sclerosis. Nature Medicine. 5: 347-50. PMID 10086395 DOI: 10.1038/6568  0.714
1998 Klivenyi P, St Clair D, Wermer M, Yen HC, Oberley T, Yang L, Flint Beal M. Manganese superoxide dismutase overexpression attenuates MPTP toxicity. Neurobiology of Disease. 5: 253-8. PMID 9848095 DOI: 10.1006/Nbdi.1998.0191  0.691
1998 Bogdanov MB, Ferrante RJ, Kuemmerle S, Klivenyi P, Beal MF. Increased vulnerability to 3-nitropropionic acid in an animal model of Huntington's disease. Journal of Neurochemistry. 71: 2642-4. PMID 9832167 DOI: 10.1046/J.1471-4159.1998.71062642.X  0.591
1998 Klivenyi P, Beal MF, Ferrante RJ, Andreassen OA, Wermer M, Chin MR, Bonventre JV. Mice deficient in group IV cytosolic phospholipase A2 are resistant to MPTP neurotoxicity. Journal of Neurochemistry. 71: 2634-7. PMID 9832165 DOI: 10.1046/J.1471-4159.1998.71062634.X  0.628
1998 Klivenyi P, Matthews RT, Wermer M, Yang L, MacGarvey U, Becker DA, Natero R, Beal MF. Azulenyl nitrone spin traps protect against MPTP neurotoxicity. Experimental Neurology. 152: 163-6. PMID 9682023 DOI: 10.1006/Exnr.1998.6824  0.686
1995 Vécsei L, Klivényi P. Somatostatin and Alzheimer's disease. Archives of Gerontology and Geriatrics. 21: 35-41. PMID 15374222 DOI: 10.1016/0167-4943(95)00640-7  0.369
Show low-probability matches.